Symptomatic Aortic Stenosis Clinical Trial
Official title:
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.
The narrowing of the aortic valve, which prevents blood from reaching the entire body correctly is a common disease in our environment. To correct this problem, many patients undergo Transcatheter Aortic Valve Implantation (TAVI) according to standard clinical practice. Patients have to continue with a specific pharmacological treatment (antiplatelet agents) to avoid possible complications during the first months after the procedure. This treatment is not yet well established. Current guidelines recommend dual antiplatelet therapy with Aspirin and Clopidogrel for 3-6 months after TAVI to avoid thromboembolic complications. But the risk of bleeding events with DAPT in this population is not negligible. This study aims to determine the degree of response to Ticagrelor 60 mg every 12 hours as a single antiplatelet strategy in patients who do not achieve an adequate response with Clopidogrel 75mg every 24 hours. The study will evaluate if patients have an adequate response to Clopidogrel and if not, then patients will start treatment with Ticagrelor 60 mg every 12 hours after TAVI and until completing 3 months of treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03003650 -
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis:CE-approval Cohort
|
N/A | |
| Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
| Active, not recruiting |
NCT04091048 -
Optimize PRO Study
|
||
| Withdrawn |
NCT03247465 -
Image Fusion and Calcification Raising in Trans Aortic Valve Implantation
|
N/A | |
| Completed |
NCT03143686 -
ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)
|
||
| Active, not recruiting |
NCT05182307 -
DurAVR™ THV System: First-In-Human Study
|
N/A | |
| Active, not recruiting |
NCT03466918 -
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
|
N/A | |
| Completed |
NCT01819181 -
Women's INternational Transcatheter Aortic Valve Implantation Registry
|
||
| Recruiting |
NCT02803294 -
Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population
|
Phase 4 | |
| Completed |
NCT02536196 -
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
|
N/A | |
| Recruiting |
NCT04861805 -
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
|
N/A | |
| Withdrawn |
NCT02088021 -
Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access
|
N/A | |
| Terminated |
NCT02759237 -
The Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance (PMS) (CoreValve India PMS)
|
N/A | |
| Recruiting |
NCT01794832 -
Severe Aortic Stenosis in Patients Referred for Valve Surgery
|
N/A | |
| Completed |
NCT02424370 -
Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation
|
||
| Completed |
NCT01493284 -
Portico TAVI Implant With Transfemoral Delivery System
|
N/A | |
| Active, not recruiting |
NCT05712161 -
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
|
N/A | |
| Completed |
NCT02664649 -
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
|
Phase 3 | |
| Completed |
NCT01487330 -
First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System
|
N/A | |
| Active, not recruiting |
NCT04722250 -
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
|
N/A |